Skip Navigation


NDT Advance Access originally published online on October 23, 2007
Nephrology Dialysis Transplantation 2008 23(1):369-373; doi:10.1093/ndt/gfm620
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
23/1/369    most recent
gfm620v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Türk, T. R.
Right arrow Articles by Witzke, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Türk, T. R.
Right arrow Articles by Witzke, O.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org


Ezetimibe treatment in hypercholesterolaemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study

Tobias R. Türk1, Eva Voropaeva1, Matthias Kohnle1, Jens Nürnberger1, Thomas Philipp1, Andreas Kribben1, Uwe Heemann2 and Oliver Witzke1

1Department of Nephrology and Hypertension, University Hospital Essen, University of Duisburg-Essen, Hufelandstraße 55, 45122 Essen and 2Department of Nephrology, Klinikum rechts der Isar der Technischen Universität, Ismaninger Straße 22, 81675 München, Germany

Correspondence to: Oliver Witzke, Priv.-Doz. Dr med, Department of Nephrology & Hypertension, University Hospital Essen, University of Duisburg-Essen, Hufelandstraße 55, D-45122 Essen, Germany. Email: oliver.witzke{at}uk-essen.de



  Abstract

Background. Ezetimibe has shown efficacy in the therapy of hypercholesterolemia in renal transplant patients. This is the first study investigating the effect of ezetimibe on renal function in kidney transplant recipients.

Methods. Fifty-six patients with statin-resistant hypercholesterolemia (total cholesterol >200 mg/dl) after renal transplantation received additional ezetimibe therapy (10 mg/day) for 12 months. A group receiving statin therapy (n = 28) served as controls in this prospective study.

Results. Total cholesterol and LDL cholesterol concentrations decreased significantly in the ezetimibe-treated patients but remained stable in the control group (delta total cholesterol: –24 ± 49 mg/dl vs 19 ± 49 mg/dl, P < 0.01; delta LDL: –30 ± 39 mg/dl vs – 3 ± 31 mg/dl, P < 0.01). Mean creatinine clearance remained stable in ezetimibe-treated patients but decreased significantly in control group (delta Cockcroft–Gault: 0.9 ± 7.3 ml/min vs – 4.8 ± 12.8 ml/min, P = 0.025; delta Modification of Diet in Renal Disease: –0.4 ± 6.2 ml/min/1.73 m2 vs 4.7 ± 8.8 ml/min/1.73 m2, P = 0.033).

Conclusions. The data of our prospective case–control study suggest that ezetimibe appears to ameliorate the decline of renal function after renal transplantation.

Keywords: allograft function; ezetimibe; hypercholesterolemia; renal transplantation

Received for publication: 27. 4.07
Accepted in revised form: 16. 8.07


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.